Submissions from 2024
Characterization of, Eric Ovruchesky, Elizabeth Pan, Melis Guer, Andrew Elliott, Shankar Siva, Praful Ravi, Bradley McGregor, Aditya Bagrodia, Ithaar Derweesh, Pedro Barata, Elisabeth I Heath, Emmanuel S Antonarakis, Sourat Darabi, Dave SB Hoon, Amir Mortazavi, Toni K Choueiri, Chadi Nabhan, Shuanzeng Wei, and Rana R McKay
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)., Pablo E Pergola, Michael Davidson, Camilla Jensen, Amir A Mohseni Zonoozi, Dominic S Raj, Philip Andreas Schytz, Katherine Tuttle, and Vlado Perkovic
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)., Pablo E Pergola, Michael Davidson, Camilla Jensen, Amir A Mohseni Zonoozi, Dominic S Raj, Philip Andreas Schytz, Katherine Tuttle, and Vlado Perkovic
Semaglutide for Chronic Kidney Disease in Type 2 Diabetes. Reply., Vlado Perkovic, Katherine Tuttle, and Richard Pratley
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes., Vlado Perkovic, Katherine R Tuttle, Peter Rossing, Kenneth W Mahaffey, Johannes F E Mann, George Bakris, Florian M M Baeres, Thomas Idorn, Heidrun Bosch-Traberg, Nanna Leonora Lausvig, Richard Pratley, and FLOW Trial Committees and Investigators
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial., Richard E Pratley, Katherine Tuttle, Peter Rossing, Søren Rasmussen, Vlado Perkovic, Olav Wendelboe Nielsen, Johannes F E Mann, Richard J MacIsaac, Mikhail N Kosiborod, Zdravko Kamenov, Thomas Idorn, Marco Bo Hansen, Samy Hadjadj, George Bakris, Florian M M Baeres, and Kenneth W Mahaffey
Perceptions of Providing Continuous Blood Glucose Data for a Research Study, Teresa Rangel and Rachel Carlson
Prevalence of Chronic Kidney Disease in Type 1 Diabetes Among Adults in the U.S., Peter Rossing, Per-Henrik Groop, Rakesh Singh, Robert Lawatscheck, and Katherine Tuttle
Preanalytical considerations in quantifying circulating miRNAs that predict end-stage kidney disease in diabetes., Eiichiro Satake, Bozena Krolewski, Hiroki Kobayashi, Zaipul I Md Dom, Joseph Ricca, Jonathan M Wilson, Dave Hoon, Kevin L Duffin, Marcus G Pezzolesi, and Andrzej S Krolewski
Universal Fetal Echocardiography for Pregestational Diabetes Mellitus: A Cost-Effectiveness Analysis., Leah M Savitsky, Caitlin Hamilton, Mary Sterrett, Kelsey Olerich, Kimberly Ma, and Catherine M Albright
Association of mental health-related patient reported outcomes with blood pressure in adults and children with primary proteinuric glomerulopathies., Matthew Schuchman, Tammy M Brady, Dorey A Glenn, Katherine Tuttle, Gabriel Cara-Fuentes, Rebecca V Levy, Agustin Gonzalez-Vicente, Fadhl M Alakwaa, Tarak Srivastava, and Christine B Sethna
Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial., Meghan E Sise, Jose Ramon Santos, Jason D Goldman, Katherine Tuttle, J Pedro Teixeira, Allan F Seibert, Yiannis Koullias, Joe Llewellyn, Sean Regan, Yang Zhao, Hailin Huang, Robert H Hyland, Anu Osinusi, Helen Winter, Rita Humeniuk, Henry N Hulter, Robert L Gottlieb, Dahlene N Fusco, Rita Birne, Fernando F Stancampiano, Claudia R Libertin, Catherine B Small, Markus Plate, Mark J McPhail, REDPINE Investigators, and Katherine Tuttle
ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): updated safety and efficacy from the phase 1 TRAVERSE multicenter study, SA Srour, Brendan Curti, and See full list of authors in comments
Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today., Howard Trachtman, Hailey Desmond, Amanda L Williams, Laura H Mariani, Sean Eddy, Wenjun Ju, Laura Barisoni, Heather K Ascani, Wendy R Uhlmann, Cathie Spino, Lawrence B Holzman, John R Sedor, Crystal Gadegbeku, Lalita Subramanian, Chrysta C Lienczewski, Tina Manieri, Scott J Roberts, Debbie S Gipson, Matthias Kretzler, NEPTUNE investigators, and Katherine Tuttle (NEPTUNE investigators)
Journal names its 25 People of Influence in 2025, Katherine Tuttle (author mention)
379. SGLT Inhibitors: The Biology of SGLT Inhibition with Dr. Katherine Tuttle, Katherine Tuttle
“Adjunctive Therapy in T1D”, Katherine Tuttle
“A Pinch of Salt – A Podcast by ERA”, Katherine Tuttle
“Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status of Risk in the FLOW Trial.", Katherine Tuttle
“Benefits of semaglutide on chronic kidney disease outcomes by cardiovascular status or risk in the FLOW trial.", Katherine Tuttle
“Building your academic career portfolio”, Katherine Tuttle
“Cardiovascular-Kidney-Metabolic Syndrome, Katherine Tuttle
“Cases in Diabetes, Kidney, and Cardio-Renal-Metabolic Disease”, Katherine Tuttle
CKD screening for better kidney health: Why? Who? How? When?, Katherine Tuttle
Clinical and Mechanistic Effects of GLP-1 Receptor Agonists in CKD, Katherine Tuttle
“Diabetic Nephropathy 2024: Comprehensive Care for People with Diabetes Mellitus and Advanced Chronic Kidney Disease.", Katherine Tuttle
“DM and CKD Treatments: Which Treatment Should I Use for Different Populations?”, Katherine Tuttle
“Effects of Semaglutide on CKD in Patients with Type 2 Diabetes (FLOW)”, Katherine Tuttle
“Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.”, Katherine Tuttle
“FLOW: A new treatment paradigm for people with T2D and chronic kidney disease”, Katherine Tuttle
“FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk.”, Katherine Tuttle
“FLOW Result: Summary and Clinical Implication, Katherine Tuttle
“FLOW: Semaglutide scores big in diabetic patients with CKD”, Katherine Tuttle
“ GLP1-RA in CKD”, Katherine Tuttle
GLP-1 Receptor Agonists for CKD in Diabetes and Beyond…, Katherine Tuttle
“GLP-1 Receptor Agonists for CKD in Diabetics and Beyond”, Katherine Tuttle
“Glycemic Management in Persons with Diabetes and CKD”, Katherine Tuttle
“Going with the FLOW: Understanding the renal effects of GLP-1RA Therapy”, Katherine Tuttle
Helio “Aldosterone inhibitor BI 690517 reduced albuminuria when combined with SGLT2 inhibitor”, Katherine Tuttle
Horizons-EASD eLearning, Katherine Tuttle
“How GLP1 receptor agonist evolved from weight management drug to kidney protective therapy”, Katherine Tuttle
“How Will the Incretin Data “FLOW” into Practice?”, Katherine Tuttle
“ Key considerations for tailoring treatment approaches for diabetic patients with chronic kidney disease", Katherine Tuttle
“Kidney Compass Podcast with Drs. Neuen/Wadhwani & Tuttle, Katherine Tuttle
“Kidney Disease and Obesity”, Katherine Tuttle
“Kidney Health for All: Advancing equitable access to care and optimal medication practice”, Katherine Tuttle
“Kidney Week 2024 Press Conference”, Katherine Tuttle
“Kidney Week 2024 Video Interview”, Katherine Tuttle
“Landmark studies”, Katherine Tuttle
“Miracle weight-loss drugs could halt kidney disease too”, Katherine Tuttle
"National Academies Workshop – Preparing the Future Workforce in Drug andResearch Development", Katherine Tuttle
National Geographic Interview feature article, Katherine Tuttle
“Navigating the Sea Change of CKD Treatment in Diabetes”, Katherine Tuttle
“Nephrology Times Interview”, Katherine Tuttle
“New study shows Ozempic lowers kidney disease”, Katherine Tuttle
“New use for Ozempic”, Katherine Tuttle
“Ozempic cuts risk in kidney disease”, Katherine Tuttle
“Ozempic cuts risk of chronic kidney disease complications, study finds””, Katherine Tuttle
“Ozempic keeps wowing: trial data show benefits for kidney disease”, Katherine Tuttle
“Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds", Katherine Tuttle
Plenary - “Kidney Health and CKD Prevention Herald a Sea Change in Nephrology”, Katherine Tuttle
Research Development., Katherine Tuttle
“Sea Change in CKD”, Katherine Tuttle
“Semaglutide cuts kidney failure and death in diabetes”, Katherine Tuttle
“Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial”, Katherine Tuttle
“Semaglutide significantly improves chronic kidney disease”, Katherine Tuttle
“State-of-are Treatment for DKD”, Katherine Tuttle
“State of the art treatment for CKD”, Katherine Tuttle
“Study crystallizes distinct kidney benefits of common drug”, Katherine Tuttle
“Success of GLP-1 receptor agonists in kidney disease halts FLOW trial early.”, Katherine Tuttle
Talk with a Doc Podcast, Katherine Tuttle
The FLOW Trial of Semaglutide for CKD in Type 2 Diabetes: Kidney, Cardiovascular, and Mortality Outcomes, Katherine Tuttle
“The Next Stage: CKM Syndrome Progression and Implications for CVD Outcomes”, Katherine Tuttle
“Therapeutic Transformation of Chronic Kidney Disease”, Katherine Tuttle
“Therapeutic Transformation of Kidney Care – Diabetes and Beyond”, Katherine Tuttle
“Transformation of CKD Care to Delivery Kidney Health”, Katherine Tuttle
“Transforming CKD Care from Evidence Generation to Implementation”, Katherine Tuttle
Transforming CKD Care from Evidence Generation to Implementation, Katherine Tuttle
“Transforming Kidney Care – Breakthrough Therapies”, Katherine Tuttle
“Transforming Kidney Care by Equitable Implementation of Breakthrough Therapies”, Katherine Tuttle
Treatment of Chronic Kidney Disease and Heart Failure Circa 2024, Katherine Tuttle
“Why diabetes miracle drugs like Ozempic are off-limits to Type 1s”, Katherine Tuttle
Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis., Katherine Tuttle, Clint W Abner, Patrick D Walker, Kaijun Wang, Andrew Rava, Jihaeng Heo, and Martin Bunke
Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis., Katherine Tuttle, Clint W Abner, Patrick D Walker, Kaijun Wang, Andrew Rava, Jihaeng Heo, and Martin Bunke
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial., Katherine Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, Maria Luiza Caramori, David Cherney, Lisa Cronin, Hiddo J L Heerspink, Christian Hugo, Masaomi Nangaku, Ricardo Correa Rotter, Arnold Silva, Shimoli V Shah, Zhichao Sun, Dorothea Urbach, Dick de Zeeuw, and Peter Rossing
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial., Katherine R Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, Maria Luiza Caramori, David Cherney, Lisa Cronin, Hiddo J L Heerspink, Christian Hugo, Masaomi Nangaku, Ricardo Correa Rotter, Arnold Silva, Shimoli V Shah, Zhichao Sun, Dorothea Urbach, Dick de Zeeuw, Peter Rossing, and ASi in CKD group
Combination therapy for kidney disease in people with diabetes mellitus., Daniël H van Raalte, Petter Bjornstad, David Z I Cherney, Ian H de Boer, Paola Fioretto, Daniel Gordin, Frederik Persson, Sylvia E Rosas, Peter Rossing, Jennifer A Schaub, Katherine Tuttle, Sushrut S Waikar, and Hiddo J L Heerspink
Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study., Chia-Shi Wang, Dorey A Glenn, Margaret Helmuth, Abigail R Smith, Andrew S Bomback, Pietro A Canetta, Gaia M Coppock, Myda Khalid, Katherine Tuttle, Raed Bou-Matar, Larry A Greenbaum, Bruce M Robinson, Lawrence B Holzman, William E Smoyer, Michelle N Rheault, Debbie Gipson, Laura H Mariani, and Cure Glomerulonephropathy (CureGN) Study Consortium
ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease., Kirk M Welker, David Joyner, Anthony W Kam, David S Liebeskind, Amit M Saindane, Colin Segovis, Noushin Yahyavi-Firouz-Abadi, and John E Jordan
Increasing U.S. Maternal Health Equity Among Immigrant Populations Through Community Engagement., Maryum Zaidi, Heidi Collins Fantasia, Rebecca Penders, Ainat Koren, and Comfort Enah
A framework towards digital twins for type 2 diabetes., Yue Zhang, Guangrong Qin, Boris Aguilar, Noa Rappaport, James T Yurkovich, Lance Pflieger, Sui Huang, Leroy Hood, and Ilya Shmulevich
Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila., Zhuxian Zhu, Jianguo Huang, Yanling Zhang, Weiwei Hou, Fei Chen, Yin-Yuan Mo, and Ziqiang Zhang
A new era in the science and care of kidney diseases., Carmine Zoccali, Francesca Mallamaci, Liz Lightstone, Vivek Jha, Carol Pollock, Katherine Tuttle, Peter Kotanko, Andrzej Wiecek, Hans Joachim Anders, Giuseppe Remuzzi, Kamyar Kalantar-Zadeh, Adeera Levin, and Raymond Vanholder
Submissions from 2023
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone., Rajiv Agarwal, Bertram Pitt, Peter Rossing, Stefan D Anker, Gerasimos Filippatos, Luis M Ruilope, Csaba P Kovesdy, Katherine Tuttle, Muthiah Vaduganathan, Christoph Wanner, Sameer Bansilal, Martin Gebel, Amer Joseph, Robert Lawatscheck, and George L Bakris
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis., Rajiv Agarwal, Wanzhu Tu, Alfredo E Farjat, Youssef M K Farag, Robert Toto, Sanjay Kaul, Robert Lawatscheck, Katja Rohwedder, Luis M Ruilope, Peter Rossing, Bertram Pitt, Gerasimos Filippatos, Stefan D Anker, George L Bakris, FIDELIO-DKD and FIGARO-DKD Investigators, and Katherine Tuttle
“Intensifying Diabetes Therapies to Achieve Personalized Treatment Goals”, Radica Alicic
Incidence of chronic kidney disease in prediabetes, Radica Alicic, Ken Daratha, Joshua J Neumiller, Katherine Tuttle, and See all authors in comments
Author Response to "Insulin Dosing Safety in CKD"., Radica Alicic, Joshua J Neumiller, Rodolfo J Galindo, and Katherine Tuttle
Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease., Radica Alicic, Joshua J Neumiller, and Katherine Tuttle
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease., Radica Z Alicic and Joshua J Neumiller
